Boothbay Fund Management LLC Purchases Shares of 80,000 Merus (NASDAQ:MRUS)

Boothbay Fund Management LLC bought a new position in shares of Merus (NASDAQ:MRUS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 80,000 shares of the biotechnology company's stock, valued at approximately $3,364,000. Boothbay Fund Management LLC owned about 0.12% of Merus as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC lifted its position in shares of Merus by 0.4% during the fourth quarter. FMR LLC now owns 6,899,521 shares of the biotechnology company's stock worth $290,125,000 after purchasing an additional 25,595 shares in the last quarter. Wellington Management Group LLP boosted its position in Merus by 21.1% in the 4th quarter. Wellington Management Group LLP now owns 3,497,653 shares of the biotechnology company's stock valued at $147,076,000 after buying an additional 610,139 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Merus by 7.1% during the third quarter. Franklin Resources Inc. now owns 2,256,504 shares of the biotechnology company's stock worth $117,722,000 after acquiring an additional 150,341 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Merus by 56.8% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock valued at $89,356,000 after acquiring an additional 770,000 shares during the period. Finally, Pictet Asset Management Holding SA boosted its holdings in Merus by 1.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,031,827 shares of the biotechnology company's stock valued at $43,388,000 after acquiring an additional 19,379 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Trading Down 0.1 %

Shares of MRUS stock traded down $0.06 on Thursday, hitting $45.45. 766,212 shares of the stock were exchanged, compared to its average volume of 710,714. The business has a 50-day moving average of $43.97 and a 200 day moving average of $44.58. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $61.61. The firm has a market capitalization of $3.14 billion, a P/E ratio of -11.51 and a beta of 1.02.

Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.48. The company had revenue of $9.14 million during the quarter, compared to analysts' expectations of $10.57 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. As a group, research analysts forecast that Merus will post -3.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on MRUS. Guggenheim restated a "buy" rating and set a $109.00 target price on shares of Merus in a research report on Friday, March 28th. Piper Sandler began coverage on Merus in a report on Thursday, February 13th. They set an "overweight" rating and a $84.00 target price on the stock. Wells Fargo & Company started coverage on shares of Merus in a research note on Friday, February 7th. They issued an "overweight" rating and a $91.00 target price for the company. Bank of America reduced their price target on shares of Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Finally, William Blair restated an "outperform" rating on shares of Merus in a research report on Monday. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $85.31.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.